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Extrapolating the figures from a previous study on FSHD in a province 
of The Netherlands to the entire Dutch population suggests that at 
present a nearly complete overview is obtained of all symptomatic kin­
dred. In 139 families, dominant inheritance was observed in 97, a pat­
tern compatible with germline mosaicism in 6, while sporadic cases 
were found in 36 families. A mutation frequency of 9.6% was calculated. 
Mentai retardation and severe retina! vasculopathy were reported in 
low frequencies (1%). Early onset was seen more frequently in sporadic 
cases. Chromosome 4 linkage appeared excluded in 3 of 22 autosomal- 
dominant families. The clinical pictures in the linked and nonlinked 
families were identical. © 1995 John Wiley & Sons, Inc.
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FACIOSCAPULOHUMERAL MUSCULAR 
DYSTROPHY IN THE 
DUTCH POPULATION
G.W. PADBERG, MD, R.R. FRANTS, PhD, O.F. BROUWER, MD,
C. WIJMENGA, PhD, E. BAKKER, PhD, and L.A, SANDKUIJL, PhD
Facioscapulohumeral muscular dystrophy 
(FSHD) has generally been described as an auto­
somal-dominant myopathy with a variable age of 
onset and a mildly progressive course.4 Therefore, 
early onset, a rapid course, and extramuscular in­
volvement such as hearing loss and retinal vascular 
pathology have been considered extraordinary 
manifestations and indications of clinical and by 
consequence genetic heterogeneity,6 Incidental ob­
servations contributed to a rather wide picture of 
FSHD, and only after several large studies of com­
pletely examined families, was it possible to recog­
nize cardiac involvement, extensive contractures, 
ptosis, and extraocular muscle weakness as not be­
ing part of autosomal-dominant FSHD.5 For such 
cases, the term “FSH syndrome” came into use.7
The discussion about possible genetic heteroge­
neity of FSHD was not easily solved as pedigrees 
without clearly autosomal-dominant patterns con-
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tinued to be observed. New insights in mechanisms 
of heredity such as germline mosaicism offered ex­
planations for multiple cases in a sibship without 
the parents being affected. The demonstration of 
the locus for FSHD on the tip of chromosome 4q 
was thought to be compatible with the suspected 
high mutation rate.8,11 But when all genetic prob­
lems seemed to be reduced to one single locus, 
families with classical FSHD were reported in 
which this locus had been excluded.3 Thus it be­
came important to have some idea about the fre­
quencies of new mutations and locus heterogeneity 
of FSHD in the population. Although it is felt that 
a population study of FSHD will never be com­
plete, this is a first attempt to give some general 
figures, as it is our impression that we have a fairly 
complete overview of the symptomatic FSHD pop­
ulation in The Netherlands.
PA TIEN TS AND METHODS
Probands of 19 autosomal-dominant FSHD fami­
lies were seen at the University Hospitals of Am­
sterdam and Leiden from 1970 to 1979, and their 
families were extensively studied in 1980—1981. 
Ten of these families participated in the genetic 
studies of 1990—1994.8,10,11 Probands of 30 other 
dominant families were seen at the University Hos­
pital in Leiden from 1986 to 1993 and during sev­
eral field studies. These families were not studied 
completely. At least all probands underwent EMG
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and muscle biopsy. DNA was collected in 22 of amined completely. These families contained, on
these 49 families. Forty-eight probands of domi­
nant families were seen in other neuromuscular 
centers at the University Hospitals during the last 
15 years. Their pedigrees were constructed by pa­
tients’ information only.
Also, 6 probands and their families were stud­
ied for possible germline mosaicism. In 3 families 
both parents, in 2 families only 1 parent, and in 1 
family none of the parents were examined. We 
were able to analyze DNA of 3 families.
Finally, from 1980 to 1993 we saw 28 sporadic 
cases and their families, DNA was sampled in 17 
cases and in 14 instances blood of both parents 
could be collected. Eight additional cases were seen 
at other neuromuscular centers,
DNA was extracted as reported previously, and 
4q35 markers including p l3E- ll were studied as 
described.10,11
R ESU LTS
After the ascertainment of 50 patients from 12 au- 
tosomal-dominant families in the province of 
North-Holland, The Netherlands, in what was felt 
to be a thorough study in 1980, a prevalence of 1 
patient per 46.000 was calculated.4 Based on the 
observation that no second probands were found 
in this apparently exhaustive study, the probability 
of ascertaining a kindred with FSHD was estimated 
to be lower than 45%, yielding an estimated prev­
alence of at least 1 patient per 21,000, which is a 
figure close to the one reported by Becker for the 
Baden-Baden population in Germany.1,4 Extend­
ing these figures to the general population of The 
Netherlands it was estimated that this country con­
tains approximately 714 patients. If  indeed a per­
centage of 30% of asymptomatic patients, as found 
in the first study,4 could be extrapolated to the 
general population, approximately 500 living 
symptomatic patients are to be expected in the 
Dutch population. Our fist study4 was aimed at the 
larger families because we were interested in doing 
linkage studies. These families contained, on aver­
age, 5.05 symptomatic patients (Table 1). In the 
second series families not all affected sibs were 
studied personally, and these families were not ex­
average, 3.9 affected sibs. Overall, our families 
contained 4.3 symptomatic sibs. Based on these fig­
ures it was to estimated to find 99—128 and, on 
average, 116 autosomal-dominant families in The 
Netherlands. At present we are aware of 97 dom­
inant families (Table 1). Families not referred to 
any of the neuromuscular centers at the university 
hospitals would be lost to inclusion. An easy access 
to the university hospitals, an intensive contact 
with primary care physicians, and a well-informed 
public in this tiny country suggests that only a small 
percentage of families have not been referred to 
these neuromuscular centers. Also, the chance of a 
family consisting entirely of asymptomatic patients 
is so small that it can be left out of the analysis. In 
conclusion, it appears that we have an almost com­
plete overview of all families with autosomal- 
dominant FSHD and, following the same reason­
ing, also probably of all sporadic cases of FSHD in 
The Netherlands.
Mutation Frequency. From these figures a muta­
tion frequency can be calculated. We have studied 
personally 28 sporadic cases and have been in­
formed of 8 additional cases at other university 
hospitals. In our own autosomal-dominant families 
we know of 4 new mutations (i.e., top of the ped­
igree). In the 48 reported dominant families we 
assume a similar number of new mutations. More­
over, we know of 6 pedigrees with strong indica­
tions of germline mosaicism of which at least 4 of 
the mutated individuals are alive. Therefore, we 
assume 48 instances of new FSHD mutations 
among an estimated number of 500 symptomatic 
living FSHD patients in The Netherlands, suggest­
ing a mutation frequency of 9.6% or 1 mutation 
per 320,000 live births as the Dutch population at 
present contains 15.4 million individuals.
Patterns of Inheritance. The family data presently 
known to us make it possible to estimate frequen­
cies of mechanisms of inheritance in FSHD (Table 
2). An autosomal-dominant pattern occurred in 97 
families (69.7%). Germline mosaicism was the most 
likely explanation for the heredity pattern in 6
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Table 2. Pattern of inheritance in 139 families.
Autosomal dominant 97 69.7%
Germline mosaicism 6 4.3%
Sporadic cases 36 25.9%
Total 139
families (4.3%). New mutations were not infre­
quent and involved 38 sporadic cases or 25.9% of 
all families with FSPID patients (Table 2).
Sex D ifferences. As there has been a long­
standing impression that males were more fre­
quently and more severely affected with FSHD, we 
looked at this matter in our 1980 study.4 In that 
study, the reported age at onset between males 
(15.8 years) and females (19.0 years) was statisti­
cally not significant. The difference in number of 
asymptomatic males (i.e., 13; 22%) and females 
(i.e., 21; 44%) was statistically not significant. Also, 
the differences in numbers of affected males and 
females were not significant in 1980 and even less 
so in the present survey (Table 1). However, the 
difference between male (15) and female (4) 
probands were statistically significant (P = 0.016; 
chi-square test) in the 1980 study.4 The probands 
that we have studied personally so far (Table 3) 
again show a statistically significant (P = 0.023; 
chi-square test) difference between males and fe­
males.
Early Onset. Early onset of FSHD, defined as 
symptomatic before the age of 10 and/or signs be­
fore the age of 5, was observed in 9 (4.2%) of 241 
personally examined cases of autosomal-dominant 
inheritance. Ten (36%) sporadic cases were of 
early onset.
Extramuscular Involvement. The present survey 
was not intended to study extramuscular involve­
ment in FSHD. Estimation of hearing loss in spo­
radic (71%) and dominant (62%) cases are pre­
sented elsewhere,6 In the same article, a retinal 
vasculopathy is reported to occur in 50% of all pa­
tients with no differences between chromosome
Table 3. ProbancJ analysis in 83 FSHD families.
Male Female Total
AD families extensively studied 15 4 19
AD families partially studied 17 13 30
Germline mosaicism 5 1 6
Sporadic cases 19 9 28
Total 56 27 83
4—linked and —non linked families; in the two chro­
mosome 4—excluded families in which retinal an­
giograms were studied, patient R II6  revealed no 
abnormalities, while both patients of family KL 
showed retinal vascular changes. This study indi­
cates that severe retinal vasculopathy, i.e., a Coats’ 
disease-like picture is quite rare as we were able to 
find only 3 patients with Coats’ disease of the 256 
(1.2%) FSHD patients under survey. As such a se­
vere complication is likely to come under the at­
tention of specialists, the chance is that the true 
incidence of severe retinal vasculopathy is even 
lower.
Similarly, mental retardation occurs in a low 
frequency in FSHD. We know of 4 male cases in 
our survey of 256 patients, which might be the only 
cases in the entire symptomatic FSHD population. 
Three of these cases have been described else­
where because of early onset,2 while the fourth 
case is discussed as the first case of a severe retinal 
vasculopathy in the addendum of our article on 
retinal pathology.6 The percentage of male pa­
tients with mental retardation might not be dif­
ferent from  the percentage of male mental 
retardation in the general population. Yet the 
combination of early onset (4 cases), hearing loss (3 
cases), and severe retinal vascular changes (2 cases) 
suggest a special configuration. The 2 cases with 
autosomal-dominant inheritance had an affected 
parent with an usual pattern of involvement and 
average severity. The demonstration of chromo­
some 4 involvement in the dominant cases sup­
ports the concept that these cases represent the 
extreme of the clinical spectrum that on the other 
end consists of facial weakness only, or even more 
rarely, nonpenetrance.
Sporadic Cases. In this survey of 139 families, 
sporadic cases occurred in 36 instances (25.9%) 
and in 28 (11%) of all 256 patients seen by us per­
sonally, Onset below the age of 10 years occurred 
in 10 of 28 sporadic cases, while this was found in
3 of 15 cases of germline mosaicism and in 9 of 213 
dominant cases. Fourteen sporadic cases showed a 
short fragment with pl3E-l 1; in 10 instances, both 
parents could be studied and in 4 cases one parent 
and other sibs were examined, all showing no short 
fragment, suggesting that these 14 sporadic cases 
were 4q-associated new mutations. In 3 cases and 
their parents, a short fragment could not be dem­
onstrated, and in 11 other cases no DNA was avail­
able for analysis.
Germline M osaicism. Among 139 pedigrees stud­
ied we found 6 with multiple cases in the same
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sibship and apparently nonaffected parents. Both 
parents had been studied in 4 families (nos. 1-4). 
In family 5, one parent and in family 6 both par­
ents were diseased. In family 3, the patients re­
vealed a short fragment with pl3E-ll, while no 
such fragment could be found in family 4. Also in 
family 5, only the patient had a short fragment. 
From families I, 2, and 6 no DNA was available.
Autosomal-Dominant Inheritance. In this study,
we obtained information on 97 families with auto­
somal-dominant FSHD. Ten of the original 19 ex­
tensively studied families participated in the link­
age studies leading to the location of the gene.8 
One small family is probably not linked.11 Later, 
12 additional families were studied; in two small 
families, no short fragment with pl3E-ll could be 
found and haplotyping suggested nonlinkage to 
4q35. Thus, in 3 of 22 families (13.6%) linkage to 
4q35 seemed excluded.
DISCUSSION
Population-based studies of FSHD always appear 
to be hazardous enterprises. With a large propor­
tion of asymptomatic patients, and many patients 
familiar with the disorder through their parents 
and relatives, and therefore often not seeking 
medical attention, FSHD is a disorder prone to un­
derestimation of its prevalence. Figures obtained 
in a small Dutch population4 turned out to be fairly 
accurate when extrapolated to the Dutch popula­
tion at large. It seems that we have reached a near 
complete ascertainment of families and index 
cases, making possible a reliable estimate of the 
mutation rate for the First time. Our figure of 1 
new mutation per 320,000 live births is again a 
rather conservative estimate. Strong arguments for 
germline mosaicism have been found which ap­
pear to occur in 4.6% of all families. This report 
clearly demonstrates that the linkage studies need 
to be extended to estimate the percentage of ge­
netic heterogeneity of FSHD more accurately; our 
figures of non-4q linkage in sporadic cases 
(17.6%) and familial cases (13.6%) are presently 
not based on sufficiently large numbers of pa­
tients.
On the clinical side, this survey has given some 
information on the low frequency of mental retar­
dation and severe retinal vasculopathy both occur­
ring in approximately 1% of the FSHD patients. 
Significant sex differences were not found with the 
exception of a male excess in the numbers of 
probands. This might be a cultural bias; we have 
no other convincing explanation for it. Also, the 
association of more severe cases, onset before the 
age of 10 in conjunction with new mutations, could 
be an ascertainment bias, but a final answer prob­
ably has to wait for the finding of the gene.
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